Published in J Bone Miner Res on August 01, 2010
Cancer to bone: a fatal attraction. Nat Rev Cancer (2011) 4.08
Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol (2011) 1.92
Myeloid-derived suppressor cells expand during breast cancer progression and promote tumor-induced bone destruction. Oncoimmunology (2012) 1.19
Integrins and bone metastasis: integrating tumor cell and stromal cell interactions. Bone (2010) 1.09
Roles of bone marrow cells in skeletal metastases: no longer bystanders. Cancer Microenviron (2011) 1.01
Integrating new discoveries into the "vicious cycle" paradigm of prostate to bone metastases. Cancer Metastasis Rev (2014) 1.00
Immunological dysregulation in multiple myeloma microenvironment. Biomed Res Int (2014) 0.98
Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells. Gene Ther (2011) 0.95
The multifaceted actions of PTHrP in skeletal metastasis. Future Oncol (2012) 0.89
Parathyroid hormone-related protein drives a CD11b+Gr1+ cell-mediated positive feedback loop to support prostate cancer growth. Cancer Res (2013) 0.87
Secretome identification of immune cell factors mediating metastatic cell homing. Sci Rep (2015) 0.81
Characterization of endocannabinoid-mediated induction of myeloid-derived suppressor cells involving mast cells and MCP-1. J Leukoc Biol (2013) 0.78
Surface antigen profiles of leukocytes and melanoma cells in lymph node metastases are associated with survival in AJCC stage III melanoma patients. Clin Exp Metastasis (2014) 0.75
Engineering the pre-metastatic niche. Nat Biomed Eng (2017) 0.75
Inflammation and cancer. Nature (2002) 53.78
IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature (2007) 16.59
Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell (2006) 13.79
Stromal fibroblasts in cancer initiation and progression. Nature (2004) 11.69
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov (2004) 9.96
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell (2008) 8.01
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell (2004) 7.61
TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell (2008) 7.60
Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood (2008) 7.15
Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell (2008) 6.78
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol (2007) 6.76
Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol (2005) 6.05
Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol (2006) 5.82
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med (2007) 5.65
Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer (2008) 4.43
Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell (2006) 4.33
Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature (2007) 4.00
Cancer: an inflammatory link. Nature (2004) 3.88
A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood (2005) 3.85
Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature (2007) 3.70
Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med (2005) 3.64
Fundamental concepts of the angiogenic process. Curr Mol Med (2003) 3.16
CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med (2005) 2.93
Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice. J Immunol (1979) 2.60
Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev (2006) 2.46
Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res (2007) 2.41
SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion. Nat Genet (2007) 2.39
Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res (2008) 2.38
Helicobacter infection is required for inflammation and colon cancer in SMAD3-deficient mice. Cancer Res (2006) 2.19
Elimination of colon cancer in germ-free transforming growth factor beta 1-deficient mice. Cancer Res (2002) 2.12
Animal model of human disease. Multiple myeloma. Am J Pathol (1988) 2.08
TGF-beta: a mobile purveyor of immune privilege. Immunol Rev (2006) 1.90
A failure of transforming growth factor-beta1 negative regulation maintains sustained NF-kappaB activation in gut inflammation. J Biol Chem (2003) 1.54
Dose-dependent cross-talk between the transforming growth factor-beta and interleukin-1 signaling pathways. Proc Natl Acad Sci U S A (2007) 1.42
HIF-1alpha regulates epithelial inflammation by cell autonomous NFkappaB activation and paracrine stromal remodeling. Blood (2008) 1.33
Cancer immunology. Cancer's bulwark against immune attack: MDS cells. Science (2008) 1.27
The dual adverse effects of TGF-beta secretion on tumor progression. Cancer Cell (2005) 1.01
Bone morphogenetic proteins. Growth Factors (2004) 8.61
E3 ubiquitin ligase Smurf1 mediates core-binding factor alpha1/Runx2 degradation and plays a specific role in osteoblast differentiation. J Biol Chem (2003) 2.34
Proteolysis of latent transforming growth factor-beta (TGF-beta )-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J Biol Chem (2002) 1.99
Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease. Blood (2011) 1.88
Bone morphogenetic protein receptor signaling is necessary for normal murine postnatal bone formation. J Cell Biol (2002) 1.88
Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Res (2006) 1.82
Smurf1 inhibits osteoblast differentiation and bone formation in vitro and in vivo. J Biol Chem (2003) 1.81
Advances in osteoclast biology: old findings and new insights from mouse models. Nat Rev Rheumatol (2011) 1.76
Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood (2007) 1.75
Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1. Cancer Res (2012) 1.75
Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases. Cancer Res (2012) 1.65
The hedgehog signaling molecule Gli2 induces parathyroid hormone-related peptide expression and osteolysis in metastatic human breast cancer cells. Cancer Res (2006) 1.62
Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer (2003) 1.58
Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP). Bone (2004) 1.57
TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling. Cancer Res (2010) 1.57
Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood (2003) 1.56
Silent information regulator (Sir)T1 inhibits NF-κB signaling to maintain normal skeletal remodeling. J Bone Miner Res (2013) 1.54
Advances in the biology of bone metastasis: how the skeleton affects tumor behavior. Bone (2010) 1.54
C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res (2003) 1.52
The pathogenesis of the bone disease of multiple myeloma. Bone (2008) 1.51
Caspase-2 deficiency enhances aging-related traits in mice. Mech Ageing Dev (2006) 1.46
The zinc finger transcription factor Gli2 mediates bone morphogenetic protein 2 expression in osteoblasts in response to hedgehog signaling. Mol Cell Biol (2006) 1.45
Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis. Mol Cancer (2010) 1.45
Model structure and control of bone remodeling: a theoretical study. Bone (2008) 1.44
NF-kappaB specifically activates BMP-2 gene expression in growth plate chondrocytes in vivo and in a chondrocyte cell line in vitro. J Biol Chem (2003) 1.35
Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev (2010) 1.32
Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood (2004) 1.29
Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging. Mol Cancer Ther (2007) 1.28
Longitudinal live animal micro-CT allows for quantitative analysis of tumor-induced bone destruction. Bone (2010) 1.26
Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells. PLoS One (2012) 1.25
Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. Br J Haematol (2007) 1.19
Eph receptors and ephrin signaling pathways: a role in bone homeostasis. Int J Med Sci (2008) 1.17
The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. Breast Cancer Res Treat (2002) 1.15
Inhibition of TGF-β signaling by 1D11 antibody treatment increases bone mass and quality in vivo. J Bone Miner Res (2010) 1.15
Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo. J Clin Invest (2002) 1.12
Inhibition of microtubule assembly in osteoblasts stimulates bone morphogenetic protein 2 expression and bone formation through transcription factor Gli2. Mol Cell Biol (2008) 1.10
Anti-transforming growth factor ß antibody treatment rescues bone loss and prevents breast cancer metastasis to bone. PLoS One (2011) 1.08
Contributions of the host microenvironment to cancer-induced bone disease. Cancer Res (2014) 1.07
Quantitative measures of femoral fracture repair in rats derived by micro-computed tomography. J Biomech (2009) 1.05
Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo. Am J Hematol (2009) 1.05
A murine model of myeloma that allows genetic manipulation of the host microenvironment. Dis Model Mech (2009) 1.04
Differential effects between the loss of MMP-2 and MMP-9 on structural and tissue-level properties of bone. J Bone Miner Res (2011) 1.04
Matrix rigidity induces osteolytic gene expression of metastatic breast cancer cells. PLoS One (2010) 1.03
Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma. Cancer (2003) 0.99
A mathematical model of bone remodeling dynamics for normal bone cell populations and myeloma bone disease. Biol Direct (2010) 0.99
Theoretical investigation of the role of the RANK-RANKL-OPG system in bone remodeling. J Theor Biol (2009) 0.98
Osteoclast-derived matrix metalloproteinase-7, but not matrix metalloproteinase-9, contributes to tumor-induced osteolysis. Cancer Res (2009) 0.98
Tumor-host cell interactions in the bone disease of myeloma. Bone (2010) 0.96
Bmp2 in osteoblasts of periosteum and trabecular bone links bone formation to vascularization and mesenchymal stem cells. J Cell Sci (2013) 0.92
Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts. J Bone Miner Res (2010) 0.88
Transdermal lovastatin enhances fracture repair in rats. J Bone Miner Res (2008) 0.85
Advances in the management of myeloma bone disease. Expert Opin Pharmacother (2005) 0.83
Bone metastasis: can osteoclasts be excluded? Nature (2007) 0.81
Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis. Mol Cancer Ther (2007) 0.80
Bisphosphonates and tumor burden. J Clin Oncol (2002) 0.80
Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Pharmacol Exp Ther (2007) 0.79
6-Thioguanine inhibition of parathyroid hormone-related protein expression is mediated by GLI2. Anticancer Res (2011) 0.78
In memoriam; Dr. Gideon Rodan. Bone (2006) 0.75
A sustained release of lovastatin from biodegradable, elastomeric polyurethane scaffolds for enhanced bone regeneration. Tissue Eng Part A (2010) 0.75
New opportunities for the management of cancer-related bone complications. Clin Adv Hematol Oncol (2009) 0.75